Specialized Ophthalmology in Seoul · Dedicated International Patient Concierge

MOHW Registered · Foreign Patient Care

en-US

Jamsil Samsung Eye Clinic LogoHome
Book Consultation
Book Consultation
How It Works
SpecialtiesServicesDoctorsArticlesBefore & AfterReviewsAbout UsContact Us
LASIK vs ICL for High Myopia: Which Surgery Is Right?

Medical Guide

LASIK vs ICL for High Myopia: Which Surgery Is Right?

LASIK vs ICL for high myopia: why laser tissue removal scales with correction, what an additive lens changes, and how night vision and follow-up differ.

Schedule a Consultation

LASIK vs ICL: Which Vision Correction Surgery Is Right for High Myopia Patients?

Medically reviewed by Dr. Cha Deok Sun, Board-certified ophthalmologist (Korean Ophthalmological Society)

For high myopia, the choice between LASIK and an implantable collamer lens is not a preference between two equivalent techniques — it is a question about whether there is enough cornea to spend. LASIK corrects by removing corneal tissue, and the amount it has to remove rises with the strength of the prescription, so at some point the arithmetic stops working. An implantable lens adds optical power without subtracting tissue, which changes that calculation entirely but introduces a different set of long-term obligations.

This article works through the high-myopia argument specifically: how ablation depth scales, what the published ectasia risk factors say about strong prescriptions, what an additive lens changes, how optical quality and night vision behave at high corrections, what reversibility does and does not mean, how the follow-up differs, and where dry eye sits in the comparison.

Why "high myopia" changes the question

A strong prescription does not simply make the same operation longer; it moves the operation closer to the limits of what the tissue allows.

The National Eye Institute describes nearsightedness as a refractive error in which the eye focuses light in front of the retina rather than on it, usually because the eyeball has grown too long or the cornea is too curved. Correction by laser works by flattening the central cornea so that its focusing power drops to match the eye's length. The flatter you need to make it, the more tissue has to come out of the middle.

That is the whole mechanism, and it has a consequence that patients with mild prescriptions never encounter. The cornea is a finite structure. Every diopter of myopic correction consumes a share of it, and the share consumed is not recoverable. For a prescription of a few diopters this is a rounding error against the thickness available. For a prescription in the double digits it becomes the central constraint on the whole decision.

The US Food and Drug Administration states the clinical consequence of this in plain terms on its LASIK pages: results are generally not as good in patients with very large refractive errors of any type. That sentence is doing a great deal of work in a comparison like this one, and it is the reason a high myope is often having a different conversation from the one their mildly nearsighted friend had.

The arithmetic of tissue removal

The variables that govern laser safety in a strongly myopic eye are documented, and they are worth knowing by name.

EyeWiki, the American Academy of Ophthalmology's reference resource, sets out the risk factors for corneal ectasia after LASIK — the progressive weakening and bulging that is the complication the whole safety margin exists to prevent. Among them it names low residual stromal bed thickness, low preoperative corneal thickness, abnormal preoperative corneal mapping, young age, high myopia, and a quantity called percent tissue altered.

The residual stromal bed is what remains underneath after the flap has been made and the tissue removed. EyeWiki explains why its thickness matters structurally: both stress-strain and tensile strength analyses indicate that the front 40 percent of the stroma is stronger than the back 60 percent, and a flap-based procedure reduces the structural contribution of exactly that stronger front portion. It records that a residual bed under 300 microns has been correlated with increased ectasia risk.

Percent tissue altered captures the same idea as a proportion rather than an absolute. EyeWiki gives the formula as flap thickness plus ablation depth, divided by the thinnest preoperative central corneal thickness, and notes that some studies have found it among the most predictive factors for ectasia even in eyes whose preoperative corneal mapping looked normal. It reports a value of 40 percent as an indicator of higher risk.

Read those two together and the high-myopia problem becomes visible. The numerator of that fraction grows with the correction, because ablation depth grows with the correction. The denominator does not grow at all. A strong prescription therefore pushes the ratio upward and the residual bed downward at the same time, from both directions.

Where the laser argument runs out

The published risk scoring makes the relationship between prescription strength and caution explicit rather than impressionistic.

EyeWiki describes the ectasia risk score system developed by Randleman and colleagues, in which several variables each contribute points and the total sorts patients into low, moderate and high risk. The weighting given to the spherical equivalent of the manifest refraction is the part relevant here. A correction weaker than 8 diopters contributes nothing. Between 8 and 10 diopters it contributes one point. Between 10 and 12 it contributes two. Between 12 and 14 it contributes three. Beyond 14 diopters it contributes four points — the same weight the system assigns to abnormal preoperative corneal mapping, to a residual stromal bed under 240 microns, and to a cornea thinner than 450 microns.

EyeWiki is careful about how that tool should be read. It describes the score as controversial in its utility, partly because screening methods have changed substantially since it was devised and now include instruments that assess the back as well as the front of the cornea, and it notes a specific criticism that the system automatically classifies anyone under 22 as at least moderate risk. It also records that ectasia has been reported after LASIK in patients with low myopia and even in hyperopic treatments, so a weak prescription is not a guarantee of anything either.

The honest conclusion from all of that is not that laser correction is unavailable above some published number. It is that as the prescription climbs, the margin between a safe plan and an unsafe one narrows, the role of every other variable grows, and the proportion of eyes for whom the surgeon says no rises steadily.

What an additive lens changes about the arithmetic

An implantable collamer lens corrects by adding optical power inside the eye, which removes corneal thickness from the equation altogether.

The FDA approved the EVO and EVO+ Visian Implantable Collamer Lens on March 25, 2022, for patients aged 21 to 45 who are nearsighted, and the toric version of the same lens for patients in the same age range who are nearsighted and also have astigmatism. The approval was granted to STAAR Surgical under premarket approval supplement P030016/S035. In the clinical study supporting it, 327 patients were enrolled; 75.9 percent of eyes reached 20/20 or better and 98.9 percent reached 20/32 or better at six months.

The FDA describes where the lens sits: in the posterior chamber, behind the iris and in front of the eye's own crystalline lens, which is left in place rather than replaced. That is what "phakic" means in this context — the natural lens is still there, and the implant is an addition to it.

Jamsil Samsung Eye Clinic's description of the EVO AQUA ICL it uses matches that anatomy and adds the device details it works with: a biocompatible collamer material, protection against ultraviolet A and B, and a central micro-hole that permits the eye's own aqueous fluid to circulate, which removes the need for a separate opening to be made in the iris and allows the implant to be introduced through a corneal incision of about 3.0 millimeters. The clinic identifies the patients it is intended for as those with severe high myopia or astigmatism and those whose corneas rule out laser correction, and names no corneal tissue removal and no myopic regression among its properties.

For a high myope, the significance of all this is a single structural fact: the correction no longer scales against a finite tissue budget. A stronger prescription means a differently powered implant, not a deeper excavation.

Optical quality at high corrections

Both routes can produce visual symptoms, and the mechanisms behind them differ in ways that matter more as the correction grows.

The FDA's account of LASIK risks is specific about what can go wrong optically. Some patients lose lines of best-corrected vision. Glare, halos or double vision can seriously affect night vision. And it draws a distinction that is easy to miss: vision under low-contrast conditions — at night, or in fog — can be worse after surgery even in a patient who reads the chart well in a bright room. Under- or over-correction can occur, glasses may still be needed, and further treatment is not always possible.

The reason this grows with the correction is geometric. A laser reshapes a central zone of the cornea; outside that zone the original curvature persists, joined to the treated area by a transition. A deeper correction makes the difference between treated and untreated curvature larger, and a pupil that opens past the treated zone at night admits light through both. That is the optical origin of halos and starbursts after strong laser corrections.

The FDA lists comparable symptoms for phakic lenses — glare, halos, double vision and poor night vision — along with possible vision loss that glasses, contacts or further surgery cannot correct, and under- or over-correction, noting that many patients do not achieve 20/20.

What differs is the source. For an implant the symptom arises from the edge of a physical device inside the eye rather than from a curvature transition on the cornea. That distinction leads directly into the pupil question.

Night vision and pupil size

Pupil behavior in darkness is one of the few preoperative findings that speaks to both routes at once, and it speaks to them differently.

For implantable lenses, the FDA is direct: a pupil that dilates in dim light to a size larger than the lens carries a higher risk of visual disturbances afterward. Large pupils appear explicitly on its list of characteristics that make someone a poor candidate for a phakic lens, alongside a low or abnormal endothelial cell count, a shallow space at the front of the eye, and an abnormal iris.

For laser correction, the FDA likewise flags large pupils — evaluated in a dark room — as a risk factor for glare, halos, starbursts and ghost images, and notes that in some patients these symptoms are debilitating enough to make night driving impractical. Its guidance adds a sobering qualification about repair: while distance vision may improve after a re-operation, it is unlikely that glare or halos will.

Jamsil Samsung Eye Clinic documents pupil-size measurement under different lighting conditions as part of the examination it performs before any vision correction procedure, alongside corneal shape and thickness, refraction and assessment of overall ocular health.

For a high myope who drives at night, works night shifts, or operates equipment in low light, this finding deserves to be raised at the consultation rather than discovered afterward. It does not automatically favor one route — a large pupil is a consideration for both — but it changes what a realistic expectation looks like, and it is one of the few inputs where the patient's own occupation is genuinely part of the clinical reasoning.

Reversibility, and what it actually means

An implant can be taken out. That is true, and it means less than it sounds.

The FDA states that additional surgery may be needed to reposition, replace or remove a phakic lens. The clinic likewise describes the implant as removable if that becomes necessary. Both statements are accurate and neither describes an undoing.

What removal restores is the eye's optical state before the implant was placed — which, for a high myope, is a strongly nearsighted eye. The correction goes away with the device. What removal does not undo is anything that happened to the eye in the interval, and the FDA's risk list includes several such things: endothelial cell loss, cataract formation, raised intraocular pressure that may require long-term glaucoma treatment, and a risk of retinal detachment that it describes as increased after intraocular surgery by an unknown amount.

Laser correction offers no equivalent at all. Tissue that has been removed from the cornea does not come back, and a re-treatment can only remove more. The FDA's guidance on enhancement is correspondingly cautious: it advises waiting until measurements are stable across two visits at least three months apart, and states that no laser company has submitted enough evidence for the agency to judge the safety or effectiveness of enhancement procedures.

So the fair statement of the difference is this. The implant route keeps an option open that the laser route closes permanently, and that option is worth something — particularly to a young patient whose eye may continue to change. But "reversible" is a description of the device, not a guarantee about the eye.

The long-term surveillance difference

This is the comparison point most often left out of a consultation, and for a high myope choosing an implant in their twenties it is the one with the longest reach.

The FDA's risk page for phakic lenses explains why a cornea with an implant behind it needs watching. Some lens designs cause the cells lining the inner face of the cornea to be lost faster than the normal rate of attrition that comes with age. If the count falls too low, the cornea clouds, and restoring clarity may require a corneal transplant. The agency also notes that cataract can develop in an eye carrying a phakic implant, and that removing the cataract then means removing both the natural lens and the implant.

The FDA adds a candid limitation to all of it: long-term data are not available, because the technology is comparatively new. That is not a criticism of the device. It is a statement about what is and is not known, and it has a practical consequence — an eye with an implant is a monitored eye, with periodic review of corneal cell counts, intraocular pressure, implant position and retinal health, indefinitely.

The clinic's own position on implanted lenses is consistent with that: postoperative follow-up should track visual acuity, intraocular pressure, implant position, inflammation and corneal endothelial health, and regular eye examinations are recommended for patients carrying a phakic intraocular lens.

A laser-corrected cornea has no comparable ongoing obligation once healing has settled. The FDA describes follow-up visits at 24 to 48 hours and then regularly for at least six months, with vision taking three to six months to stabilize. After that, barring a problem, the eye returns to ordinary eye-care intervals.

For an international patient this difference is not abstract. One route produces a defined period of postoperative review. The other produces a lifelong relationship with eye care wherever the patient happens to live, and that is worth thinking through before the operation rather than after it.

The dry-eye difference

Dryness after refractive surgery is a corneal phenomenon, and that single fact places the two routes on opposite sides of it.

The FDA states that severe dry eye syndrome can occur after LASIK, that the eye may be unable to produce enough tears to stay moist and comfortable, that the condition may be permanent, and that intensive drop treatment or plugs placed in the tear drainage may be required. Its guidance on who should not have the procedure treats pre-existing dry eye as a screening issue in its own right and notes that the procedure tends to make dryness worse. The National Eye Institute's dry eye material describes the same symptom picture — a scratchy or burning sensation, blurred vision, light sensitivity — and notes that it can interfere with ordinary activities such as reading or using a computer.

The mechanism is the corneal nerve supply, which is interrupted when the cornea is cut and ablated and which takes time to recover. It is why the complaint is near-universal in the early weeks after laser correction and why in a minority it persists.

An intraocular implant does not ablate the cornea. The clinic lists a low risk of dry eyes among the properties of the EVO AQUA ICL and gives avoidance of corneal change as one of the main reasons patients request it. That is a coherent argument, and for a patient with an existing tear-film complaint it is often the single most decisive item in the comparison.

Two qualifications keep it honest. An implant still requires a corneal incision, so the eye is not untouched. And dryness has many causes unrelated to surgery, so an implant is not a treatment for a dry eye that was already dry.

What each route asks before it is even possible

Some requirements are structural and apply before any of the above is relevant.

  • Age. The FDA notes that no phakic lens is approved for people under 21, and that some have not been studied in people over 45; the EVO approval covers 21 to 45. The clinic's own stated requirement for its implantable lens pathway is a minimum age of 18 with vision stable for at least six months.
  • Stability. The FDA treats a prescription that has changed within the last 6 to 12 months as a reason for caution, and notes this is more likely in the early twenties and younger, during pregnancy or breastfeeding, with fluctuating hormones, or on certain medications. The clinic states that its implantable lens pathway is not suitable for patients who are pregnant or within three months of finishing breastfeeding.
  • Ocular history. The FDA names prior uveitis, posterior-segment disease such as proliferative diabetic retinopathy or previous retinal detachment, autoimmune disease, diabetes, and steroid or retinoic acid use among the circumstances that make someone a poor candidate for a phakic lens, and states that safety has not been studied in glaucoma, ocular hypertension, or eyes with previous injury or surgery.
  • Contact lenses out, and for how long. Two sets of instructions exist and they differ. The FDA advises stopping soft lenses two weeks before the evaluation, toric soft or rigid gas permeable lenses at least three weeks before, and hard lenses at least four weeks before, warning that measurements taken too early produce a poor surgical plan. The clinic's own instruction for its implantable lens pathway is soft lenses out seven days before, astigmatism-correcting soft or hard lenses fourteen days before, and orthokeratology lenses one month before. Where the two differ, following the longer interval and confirming the plan with the clinic is the conservative course.

How this is decided in practice at the clinic

Jamsil Samsung Eye Clinic offers both routes and describes the choice as one made on examination findings rather than on patient preference stated in advance.

Its vision correction service covers Clear Smile LASIK, corneal strengthening LASEK, High Premium LASEK and Z8 Premium LASIK on the laser side, and the EVO AQUA ICL and toric implantable lens on the intraocular side. Among the reasons it gives for patients selecting the clinic is the breadth of that option set — specifically that treatments exist for high myopia, for thin corneas and for presbyopia, which allows the approach to follow the eye rather than the other way round. For the implantable lens it describes a full dilated examination including a retinal check to confirm suitability, recommends morning appointments so that a short-lived rise in eye pressure can be watched through the day, and notes that near vision stays blurry for about a day afterward. Four board-certified ophthalmologists practice there, and the procedure its team recommends is the one the examination supports.

Accounts written by people who have been through that assessment are collected in the clinic's patient reviews. If you want the question answered for your own eyes, the route is to send your prescription history and ask for an assessment through the consultation and booking page. Charges follow the individual plan and arrive as a written quotation; take those figures from the clinic directly.

The Bottom Line

  • Laser correction consumes corneal tissue in proportion to the prescription, and EyeWiki's percent-tissue-altered formula shows why a strong correction pushes a cornea toward its limits from two directions at once.
  • EyeWiki's published ectasia risk score weights a spherical equivalent beyond 14 diopters as heavily as abnormal preoperative corneal mapping or a cornea thinner than 450 microns, while noting the tool itself is debated.
  • The FDA approved the EVO and EVO+ Visian Implantable Collamer Lens on March 25, 2022 for nearsighted patients aged 21 to 45, and the toric version for nearsighted patients with astigmatism in the same age range.
  • An implant can be removed, but the FDA notes that endothelial cell loss, cataract, raised eye pressure and an increased retinal detachment risk are not undone by removal, and that long-term data are not yet extensive.
  • The FDA describes severe and sometimes permanent dry eye as a LASIK risk and treats existing dryness as a screening issue, which is why tear-film status often decides the comparison on its own.

Frequently Asked Questions

Is there a prescription above which LASIK stops being possible?

There is no single published cutoff, but the margin narrows steadily. EyeWiki's ectasia risk score gives increasing weight to stronger corrections, reaching its maximum weighting beyond 14 diopters, and the FDA states that results are generally not as good in patients with very large refractive errors. What decides any individual case is the combination of prescription strength, corneal thickness and corneal mapping together.

Does an implantable lens avoid the ectasia question entirely?

It avoids the mechanism that causes it, because no corneal tissue is removed and no flap is made. The structural concern EyeWiki describes arises from reducing the contribution of the stronger front portion of the corneal stroma, which an intraocular implant does not do. The implant brings its own risk set instead, which the FDA documents separately.

Which option is better for night vision?

Neither is automatically better. The FDA lists glare, halos, double vision and poor night vision as possible after both, and flags large pupils in dim light as a risk factor for both. For an implant it specifies the concern precisely: a pupil that opens wider than the device in low light carries a higher risk of visual disturbances.

If I have an implant placed now, what does follow-up look like in twenty years?

It looks like continuing review. The FDA explains that some phakic lens designs accelerate loss of the cells lining the inner cornea, that cataract can develop, and that pressure can rise and require treatment, and it notes that long-term data are not yet extensive. The clinic states that follow-up should track visual acuity, eye pressure, implant position, inflammation and corneal endothelial health on an ongoing basis.

Will either option prevent my nearsightedness from getting worse?

Neither changes the underlying anatomy of a long eye. The National Eye Institute explains that nearsightedness arises when the eyeball grows too long or the cornea is too curved, and surgery addresses the focus rather than the length. This is also why the FDA treats refractive stability over the preceding 6 to 12 months as a precondition.

I have had dry eyes for years. Does that settle it?

It weighs the comparison substantially. The FDA treats existing dry eye as a screening issue for laser correction and notes the procedure tends to worsen it, and describes severe post-LASIK dryness that may be permanent. An implant leaves the cornea largely intact, and the clinic lists a low likelihood of dryness among the properties of the lens it uses — but an existing dry eye still needs its own assessment.

How long must I be out of contact lenses before being measured?

Longer than most people expect, and the two published instructions differ. The FDA advises two weeks for soft lenses, at least three for toric or rigid gas permeable, and at least four for hard lenses. The clinic's instruction for its implantable lens pathway is seven days for soft lenses, fourteen for astigmatism-correcting soft or hard lenses, and one month for orthokeratology lenses.

This article is for general informational purposes and does not constitute individualized medical advice. It is not a self-diagnosis tool. Surgical candidacy, technique, and expected outcomes can only be determined through a consultation with a qualified ophthalmologist.

More Articles

Continue reading our clinical ophthalmology guides.

View All
LASIK Cost Korea vs US: How Each System Sets Prices

LASIK Cost Korea vs US: How Each System Sets Prices

LASIK cost in Korea vs the US differs because each system treats vision correction as elective. How pricing is structured, and how to request a real quote.

Learn More

Learn More
Dr. Kim Byoung Jin: Ophthalmologist in Seoul, Korea

Dr. Kim Byoung Jin: Ophthalmologist in Seoul, Korea

Dr. Kim Byoung Jin is a board-certified ophthalmologist and representative director at Jamsil Samsung Eye Clinic, Seoul. His training and focus, explained.

Learn More

Learn More
Book an Online Consultation: Korea Eye Clinic Guide

Book an Online Consultation: Korea Eye Clinic Guide

Book an online consultation with a Korea eye clinic: the channels this Seoul practice documents, the time-zone arithmetic, and what to assemble up front.

Learn More

Learn More

Jamsil Samsung Eye Clinic

Jamsil Samsung Eye Clinic in Songpa-gu, Seoul offers LASIK, LASEK, ICL, cataract, presbyopia, retina, and dry eye care from four board-certified ophthalmologists.

Treatments

SpecialtiesServicesMedical TeamMedical Articles

Patient Guide

About UsHow It WorksBefore & AfterPatient ReviewsPress & Media

Information & Legal

Contact & LocationSite SearchPrivacy PolicyRefund PolicyTerms of Use

© Jamsil Samsung Eye Clinic. All rights reserved.

Clinical evaluation is required prior to all ophthalmic procedures. Individual outcomes may vary.